BELMONT, Calif.--(EON: Enhanced Online News)--LakePharma, Inc., the leading provider of early phase protein and antibody engineering services, is hosting an Antibody Engineering Symposium in South San Francisco on Friday, October 4, 2013.
“and the Bay Area is home to many of the key players in the field. We have assembled an excellent array of speakers who are leaders in the antibody engineering field.”
The one-day conference will focus on the latest developments in antibody discovery and protein engineering, including innovative technologies that are shaping the next generation of protein therapeutics. “The market for monoclonal antibody therapeutics is soaring,” says LakePharma CEO Hua Tu, “and the Bay Area is home to many of the key players in the field. We have assembled an excellent array of speakers who are leaders in the antibody engineering field.” The Symposium will be held at the Embassy Suites, conveniently located in South San Francisco and will feature speakers from Merck, Pfizer, Sutro, and other biotech companies at the forefront of antibody engineering.
Interested participants can find out more information for the symposium on LakePharma’s web site: www.lakepharma.com/AES.
LakePharma is a leading contract research organization (CRO) specializing in antibody and protein engineering, cell line development, and protein production. Located in the heart of the San Francisco Bay Area, LakePharma has developed numerous in-house technology platforms to provide cost-effective and high quality services to its customers. Services can be fully integrated, creating a one-stop-shop solution for all of a customer’s molecular biology, cell line, and protein needs.
For more information, www.lakepharma.com